RNA, U6 small nuclear 1011, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-1011P profile across patient tissues and cancer cell-line models. RNU6-1011P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RNU6-1011P is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, RNU6-1011P RNA expression shows 16,091 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where RNU6-1011P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-1011P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-1011P survival associations across molecular data types. RNU6-1011P RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-1011P RNA expression–survival associations across cancer types. High RNU6-1011P expression shows unfavorable associations in KIRP, UVM, KIRC, ACC and CESC, but favorable associations in HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RNU6-1011P RNA expression.
This table summarizes RNU6-1011P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-1011P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-1011P shows lower tumor expression in THCA and UCEC and higher tumor expression in KIRC, LIHC, CHOL and STAD. The KIRC box plot shows higher RNU6-1011P RNA expression in tumor versus normal tissue (log2 FC = +0.664, t-test p < 0.001).
This table shows molecular features associated with RNU6-1011P in patient tissues and cancer cell lines. In patient samples, RNU6-1011P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
